In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Chromadex (CDXC – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.65.
According to TipRanks, Selvaraju is an analyst with an average return of -6.9% and a 32.00% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Regulus, and Anavex Life Sciences.
Chromadex has an analyst consensus of Moderate Buy, with a price target consensus of $5.80.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.24 and a one-year low of $1.15. Currently, Chromadex has an average volume of 73.86K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Chromadex Corp. is a nutraceutical company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Irvine, CA.
Read More on CDXC:
